Abstract
Objective: Severe brain edema is one of the most difficult problems of nervous system disease and trauma. The study evaluates the clinical application and value of bevacizumab targeted treatment in severe cerebral edema using medical image analysis and health informatics. Methods: A retrospective study was performed on 29 patients with severe cerebral edema underwent bevacizumab targeted therapy in Nanshan Hospital of Guang dong Medical University from March 2014 to January 2016. Health information like the dynamic head MRI, namely MRI image analysis, and Glass Coma Scale (GCS) score were used to evaluate patients 3 weeks after surgery, the subsequently modified Rankin scale was used to evaluate the quality of life of patients, 6 months after treatment. Results: Bevacizumab reversed the brain edema damage, general markedly effective time at the first week after treatment, in 2–3 weeks sustained significant effect. The degree of cerebral edema was significantly reduced 3 weeks after treatment, the range of edema was significantly reduced, GCS score was significantly higher than pre-treatment, and the modified Rankin scale score reduced significantly compared with pre-treatment, all of which had statistical significance (P < 0.01). Conclusion: Preliminary evaluation of bevacizumab targeted treatment in severe cerebral edema can significantly promote the brain edema subsided, reverse lesion and improve overall clinical outcome.